Perspective Therapeutics, Inc. (CATX)
About Perspective Therapeutics, Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2018
- $5.9M
- Net income
- -$103.1M
- Total assets
- $267.0M
- Market cap
- $345.6M
- Operating margin
- -6250.8%
- Net margin
- -5596.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.5M
- Operating expenses
- $92.3M
- Operating income
- -$90.9M
- Income tax
- -$2.1M
- Net income
- -$81.4M
- EPS (basic)
- $-1.23
- EPS (diluted)
- $-1.23
Balance sheet
- Total assets
- $341.1M
- Current assets
- $231.2M
- Total liabilities
- $50.4M
- Current liabilities
- $18.2M
- Shareholders’ equity
- $290.7M
Cash flow
- Operating cash flow
- -$18.3M
- Investing cash flow
- -$218.9M
- Financing cash flow
- $289.4M
- Net cash flow
- $52.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $345.6M
- EPS (diluted)
- $-1.23
- Shares outstanding
- 118.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 29, 2003
Perspective Therapeutics, Inc. (CATX) Stock Price
- Reported a net loss of $103.1M in FY2018.
- Revenue grew 1% from FY2023 to FY2024.
- Trading 48% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Perspective Therapeutics, Inc..
Write a review
News about Perspective Therapeutics, Inc.
News & sentiment via Polygon.io
Perspective Therapeutics, Inc.: frequently asked questions
Is Perspective Therapeutics, Inc. an American company?
Perspective Therapeutics, Inc. is a US-based company headquartered in Seattle, Washington, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Perspective Therapeutics, Inc. headquartered?
Perspective Therapeutics, Inc. is headquartered in Seattle, Washington, United States.
Is Perspective Therapeutics, Inc. publicly traded?
Yes — Perspective Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol CATX on the NYSE.
What does Perspective Therapeutics, Inc. do?
Perspective Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
